EXAS - Exact Sciences Corporation

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

47.52

+0.72 (+1.54%)

At close: 4:00PM EDT

Stock chart is not supported by your current browser

Previous Close	46.80
Open	46.63
Bid	47.35 x 100
Ask	47.70 x 100
Day's Range	46.28 - 47.84
52 Week Range	23.71 - 63.60
Volume	1,094,752
Avg. Volume	2,548,480

Market Cap	5.747B
Beta	1.08
PE Ratio (TTM)	N/A
EPS (TTM)	-0.99
Earnings Date	Apr 26, 2018
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	56.91

Trade prices are not sourced from all markets

All

News

Press Releases

Markit6 days ago
See what the IHS Markit Score report has to say about Exact Sciences Corp.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
ACCESSWIRE9 days ago
Today’s Research Reports on Trending Tickers: Exact Sciences and Immunomedics
NEW YORK, NY / ACCESSWIRE / April 13, 2018 / U.S. markets jumped Thursday as investor's attention shifted from current geopolitical tensions to the upcoming earnings season. Bank stocks were the top gainers ...
ACCESSWIRE12 days ago
Today’s Research Reports on Trending Tickers: Exact Sciences and Exelixis
NEW YORK, NY / ACCESSWIRE / April 10, 2018 / U.S. markets rallied in early trading Monday on the strength of technology stocks and the easing of trade relations between the U.S. and China. However, most ...
PR Newswire13 days ago
Exact Sciences schedules first-quarter 2018 earnings call
MADISON, Wis., April 9, 2018 /PRNewswire/ -- Exact Sciences Corp. (EXAS) today announced that the company plans to release its first-quarter 2018 financial results after the close of the U.S. financial markets on April 26, 2018. Following the release, company management will host a webcast and conference call at 5 p.m. EDT to discuss financial results and business progress.
InvestorPlace13 days ago
Exact Sciences Corporation Could Break Out Despite Steep Drop in Biotech
EXAS stock is down almost 29% in the same period. Exact is a promising laboratory and research firm in the business of screening patients for colon cancer. Patient compliance for the screening test is at a modest 65% .
Motley Fool14 days ago
Is Exact Sciences Corp. Still a Buy in 2018?
Shareholders in the innovative colon cancer test specialist have enjoyed huge gains over the last few years.
Investopedia16 days ago
Biotech's Exact Sciences Seen Plunging 25%
With shares around $38.75, options traders are betting the stock falls by another 25% by Dec. 31.
ACCESSWIRE16 days ago
Free Post Earnings Research Report: Exact Sciences’ Quarterly Revenues Jumped 148.02%
Stock Monitor: Biocept Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 6, 2018 / Active-Investors.com has just released a free earnings report on Exact Sciences Corp. (NASDAQ: EXAS ) ("EXAS"). ...
Benzinga19 days ago
BTIG Expects 55% Upside In Exact Sciences
The 35-percent sell-off in shares of EXACT Sciences Corporation (NASDAQ: EXAS ) offer an attractive entry point, according to BTIG Research. The molecular diagnostics product company's main product is ...
ACCESSWIRElast month
Biotricity: A Little Known Stock That Could Be The Next AXGN or EXAS
Axogen and Exact Sciences have been big winners in the healthcare sector as they've launched new and attractive products into big addressable markets. Many investors overlooked these opportunities because ...
Thomson Reuters StreetEventslast month
Edited Transcript of EXAS earnings conference call or presentation 22-Feb-18 10:00pm GMT
Q4 2017 Exact Sciences Corp Earnings Call
American City Business Journalslast month
Exact Sciences names president to lead Cologuard product
Mark Stenhouse is currently vice president of U.S. immunology at Chicago-based AbbVie.
ACCESSWIRElast month
Today’s Research Reports on Trending Tickers: BeiGene and Exact Sciences
NEW YORK, NY / ACCESSWIRE / March 20, 2018 / The S&P 500 and the Nasdaq posted their worst daily loss since February 8th on Monday as a sharp decline in Facebook shares triggered a selloff in the technology ...
Motley Foollast month
Harry Connick Jr. Hasn't Gotten Investors Jazzed Up About Exact Sciences -- Should They Be?
Exact Sciences' campaign featuring the entertainer and his wife isn't what the market expected.
PR Newswirelast month
Mark Stenhouse to join Exact Sciences as President, Cologuard
MADISON, Wis., March 20, 2018 /PRNewswire/ -- Exact Sciences Corp. (EXAS), the company that developed and commercialized Cologuard®, the only FDA-approved, noninvasive stool DNA-based test for early detection of colorectal cancer, today announced that Mark Stenhouse has been appointed to the new role of president, Cologuard. Stenhouse, vice president, U.S. Immunology at AbbVie, will assume this new position on April 2, 2018. "More than 85 million people are eligible to be screened with Cologuard, and Mark brings the experience and passion to help us reach further into this enormous population," said Kevin Conroy, chairman and CEO of Exact Sciences.
PR Newswirelast month
Harry Connick, Jr. and Wife and Cancer Survivor Jill Connick Team Up to Urge People 50 and Older to Get Screened for Colon Cancer
MADISON, Wis., March 19, 2018 /PRNewswire/ -- Grammy and Emmy award winner, and Tony award nominee, the multi-talented musician, singer and actor Harry Connick, Jr. and his wife of 24 years and former model, Jill Connick, recently marked the fifth anniversary of Jill's recovery from breast cancer. As Jill credits timely screening and early detection for being a cancer survivor today, she is joining Harry to share their experience and to raise awareness of another cancer for which timely screening is critical: colon cancer.* Their efforts will support The New 50, a public education campaign sponsored by Exact Sciences, that debuts today during Colorectal Cancer Awareness Month. "I know firsthand the value of early detection," said Connick.
Markitlast month
See what the IHS Markit Score report has to say about Exact Sciences Corp.
Exact Sciences Corp NASDAQ:EXAS
Simply Wall St.last month
Exact Sciences Corporation’s (NASDAQ:EXAS) Profit Outlook
Exact Sciences Corporation’s (NASDAQ:EXAS): Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. On 31Read More...
American City Business Journalslast month
Exact Sciences finds winning combo in Jerry Kelly and the PGA Tour Champions
Did anyone notice that the PGA golfer wearing the Cologuard hat came close to winning the inaugural Cologuard Classic golf tournament last weekend? If that pro golfer from Madison, Jerry Kelly, had won, it would have scored a unique double victory for the owner of Cologuard, Madison-based Exact Sciences Corp. Exact Sciences (EXAS) secured title sponsorship of the former Tucson Conquistadores Classic PGA Tour Champions event in Tucson, Ariz., late last year as part of its national marketing efforts for the company’s Cologuard product.
Markitlast month
See what the IHS Markit Score report has to say about Exact Sciences Corp.
Exact Sciences Corp NASDAQ:EXAS
Motley Fool2 months ago
Here's Why Exact Sciences Shares Fell 10.3% in February
The company could face competitive challenges someday.
GuruFocus.com2 months ago
Steve Mandel Expands Reach in Health Care Space With Exact Sciences
Guru takes an interest in medical diagnostics company
GlobeNewswire2 months ago
Detailed Research: Economic Perspectives on Exact Sciences, KapStone Paper and Packaging, Spirit Realty Capital, KLA-Tencor, New Residential Investment, and Brookdale Senior Living — What Drives Growth in Today's Competitive Landscape
NEW YORK, March 06, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
PR Newswire2 months ago
Mayo Clinic's Dr. Paul Limburg to join Exact Sciences medical leadership
MADISON, Wis., March 6, 2018 /PRNewswire/ -- Exact Sciences Corp. (EXAS) today announced that Paul J. Limburg, M.D., M.P.H., has been appointed the company's co-chief medical officer. Dr. Limburg is a gastroenterologist and a professor of medicine at Mayo Clinic. "We are delighted to welcome Dr. Limburg and believe he'll play a critical leadership role in our mission to eradicate colon cancer," said Kevin T. Conroy, chairman and CEO of Exact Sciences.
PR Newswire2 months ago
Jerry Kelly Issues Cologuard Challenge, Urging Fellow PGA TOUR Champions Players to Get Screened for Colon Cancer
TUCSON, Ariz., March 1, 2018 /PRNewswire/ -- Three-time PGA TOUR Champions winner Jerry Kelly is raising the bar on his competitors when it comes to colon cancer screening. At a players-only meeting before the Cologuard Classic today, Kelly urged his friends and competitors to get screened for colon cancer. Throughout the season, Kelly will be asking PGA TOUR Champions pros to take the Cologuard Challenge, a pledge which asks them to talk to their health care provider and get screened for colon cancer.